Role of dopamine agonists in Parkinson’s disease: an update

References

• Obeso JA, Rodriguez-Oroz MC, Rodriguez M et al. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol. Sci.17, 51–55 (2002).
   PubMedGoogle Scholar
• Pavese N, Evans AH, Tai YF et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology67(9), 1612–1617 (2006).
   PubMed Web of Science ®Google Scholar
• Calne DB. Treatment of Parkinson’s disease. N. Engl. J. Med.30(14), 1021–1027 (1993).
   Google Scholar
• Bennett JP Jr, Piercey MF. Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease. J. Neurol. Sci.163(1), 25–31 (1999).
   PubMed Web of Science ®Google Scholar
• Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology65(2 Suppl. 1), S3–S5 (2005).
   PubMedGoogle Scholar
• Bonuccelli U. Comparing dopamine agonists in Parkinson’s disease. J. Neurol. Sci.16(Suppl. 1), S13–S19 (2003).
   Google Scholar
• Canesi M, Antonini A, Mariani CB et al. An overnight switch to ropinirole therapy in patients with Parkinson’s disease. J. Neural Transm.106, 925–929 (1999).
   PubMed Web of Science ®Google Scholar
• Ulm G, Schuler P. For the MODAC Study Group. Cabergoline versus pergolide: a video-blinded, randomized, multicenter cross-over study. Akt. Neurologie25, 360–365 (1999).
   Google Scholar
• Hanna PA, Ratkos L, Ondo et al. Switching from pergolide to pramipexole in patients with Parkinson’s disease. J. Neural Transm.108, 63–70 (2001).
   PubMed Web of Science ®Google Scholar
• Kartzinel R, Teychenne P, Gillespie MM et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet2(7980), 272–275 (1976).
   PubMedGoogle Scholar
• Lieberman AN, Kupersmith M, Gopinathan G et al. Bromocriptine in Parkinson disease: further studies. Neurology29(3), 363–369 (1979).
   PubMedGoogle Scholar
• McDonald RJ, Horowski R. Lisuride in the treatment of parkinsonism. Eur. Neurol.22(4), 240–255 (1983).
   PubMedGoogle Scholar
• Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov. Disord.9(1), 40–47 (1994).
   PubMed Web of Science ®Google Scholar
• Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology43(3), 613–616 (1993).
   PubMedGoogle Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology49(1), 162–168 (1997).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology51(4), 1057–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Rascol O, Lees AJ, Senard JM et al. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv. Neurol.69, 531–534 (1996).
   PubMedGoogle Scholar
• Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov. Disord.11(3), 327–329 (1996).
   PubMed Web of Science ®Google Scholar
• Cristina S, Zangaglia R, Mancini F et al. High dose ropinirole in advanced Parkinson’s disease with severe dyskinesias. Clin. Neuropharmacol.26(3), 146–150 (2003).
   PubMed Web of Science ®Google Scholar
• Odin P, Oehlwein C, Storch A et al. Efficacy and safety of high-dose cabergoline in Parkinson’s disease. Acta Neurol. Scand.113(1), 18–24 (2006).
   PubMedGoogle Scholar
• Rinne UK, Bracco F, Chouza C et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology48(2), 363–368 (1997).
   PubMed Web of Science ®Google Scholar
• Barone P, Bravi D, Bermejo-Pareja F et al. Pergolide monotherapy in the treatment of early Parkinson’s disease. A randomized controlled study. Neurology53, 573–599 (1999).
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Senard JM et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J. Neurol. Neurosurg. Psychiatr.57(9), 1034–1038 (1994).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology49, 724–728 (1997).
   PubMed Web of Science ®Google Scholar
• Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology49, 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. (056 Study Group). N. Engl. J. Med.342(20), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA284(15), 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Bracco F, Battaglia A, Chouza C et al. PKDS009 Study Group. Long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs18(11), 733–746 (2004).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov. Disord.21, 343–353 (2006).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287(13), 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology37(5), 826–828 (1987).
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Iorio AD et al. End-of-dose deterioration in non-ergolinic dopamine agonist monotherapy of Parkinson’s disease. J. Neurol.253(12), 1633–1639 (2006).
   PubMed Web of Science ®Google Scholar
• Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson’s disease: a review of the literature. Clin. Ther.29, 112–125 (2006).
   Google Scholar
• Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease. Is rapid titration preferable to slow? Neurology52, 1227–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Patton G, Neilson S, Boroojerdi B. Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson’s disease. Presented at: The First World Parkinson Congress. Washington DC, USA, 22–26 February 2006.
   Google Scholar
• Stocchi F, Vacca L, Berardelli A et al. Dual dopamine agonist treatment in Parkinson’s disease. J. Neurol.250(7), 822–826 (2003).
   PubMedGoogle Scholar
• The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch. Neurol.60(12), 1721–1728 (2003).
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology68(4), 272–276 (2007).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol.64(5), 676–682 (2007).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology68(16), 1262–1267 (2007).
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N et al. SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol.6, 513–520 (2007).
   PubMed Web of Science ®Google Scholar
• Factor SA. Intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology62(Suppl. 4), 12–17 (2004).
   PubMed Web of Science ®Google Scholar
• Colzi A,Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesia in Parkinson’s disease. J. Neurol. Neurosur. Psychiatr.64, 573–576 (1998).
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A et al. Continuous sc apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov. Disord.20(2), 151–157 (2005).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Vacca L et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain125, 2058–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA et al. EASE-PD Adjunct Study Investigators. Ropinirole 24 h prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology68(14), 1108–1115 (2007).
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson’s disease. Expert Rev. Neurother.6(1), 81–89 (2006).
   PubMedGoogle Scholar
• Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur. J. Pharmacol.200(1), 65–72 (1991).
   PubMed Web of Science ®Google Scholar
• Uberti D, Carsana T, Francisconi S et al. A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-κB nuclear translocation. Biochem. Pharmacol.67(9), 1743–1750 (2004).
   PubMedGoogle Scholar
• Gu M, Iravani MM, Cooper JM et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem.91(5), 1075–1081 (2004).
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Kosaka T, Kakimura JI et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol.54(6), 1046–1054 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection. Ann. Neurol.44(Suppl. 1), S175–S188 (1998).
   PubMed Web of Science ®Google Scholar
• Hurelbrink CB, Barker RA. Prospects for the treatment of Parkinson’s disease using neurotrophic factors. Expert Opin. Pharmacother.2(10), 1531–1543 (2001).
   PubMedGoogle Scholar
• Scheller D, Chan P, Li Q et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson’s disease. Exp. Neurol.203(2), 415–422 (2007).
   PubMed Web of Science ®Google Scholar
• Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin. Neuropharmacol.26(3), 109–111 (2003).
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Wilcox PG, Churg A et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch. Intern. Med.148, 2231–2236 (1988).
   PubMed Web of Science ®Google Scholar
• Pritchett AM, Morrison JF, Edwards WD et al. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc.77(12), 1280–1286 (2002).
   PubMed Web of Science ®Google Scholar
• Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson’s disease treated with high dose pergolide. Neurology61, 859–861 (2003).
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med.356(1), 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med.356(1), 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Junghanns S, Fuhrmann JT, Simonis G et al. Valvular heart disease in Parkinson’s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov. Disord.22(2), 234–238 (2007).
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med.337, 581–588 (1997).
   PubMed Web of Science ®Google Scholar
• Botero M, Fuchs R, Paulus DA et al. Carcinoid heart disease: a case report and literature review. J. Clin. Anesth.14(1), 57–63 (2002).
   PubMedGoogle Scholar
• Redfield MM, Nicholson WJ, Edwards WD et al. Valve disease associated with ergot-derivates alkaloid use: echocardiographic and pathologic correlations. Ann. Intern. Med.117, 50–52 (1992).
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5–HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation102, 2836–2841 (2000).
   PubMed Web of Science ®Google Scholar
• Horowski R, Jähnichen S, Pertz HH. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov. Disord.19(12), 1523–1524 (2004).
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Cussac D, Quentric Y et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes. J. Pharmacol. Exp. Ther.303(2), 815–822 (2002).
   PubMed Web of Science ®Google Scholar
• Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson’s disease: a wake-up call. Mov. Disord.15, 601–603 (2000).
   PubMedGoogle Scholar
• Cantor CR, Stern MB. Dopamine agonists and sleep in Parkinson’s disease. Neurology58(Suppl. 1), S71–S78 (2002).
   PubMedGoogle Scholar
• Korner Y, Meindorfner C, Moller JC et al. Predictors of sudden onset of sleep in Parkinson’s disease. Mov. Disord.19, 1298–1305 (2004).
   PubMed Web of Science ®Google Scholar
• Avorn J, Schneeweiss S, Sudarsky LR et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch. Neurol.62, 1242–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Gjerstad MD, Alves G, Wentzel-Larsen T et al. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology67(5), 853–858 (2006).
   PubMed Web of Science ®Google Scholar
• Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep25(8), 905–909 (2002).
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov. Disord.18(3), 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol.62(9), 1377–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Grosset KA, Macphee G, Pal G et al. Problematic gambling on dopamine agonists: not such a rarity. Mov. Disord.21(12), 2206–2208 (2006).
   PubMed Web of Science ®Google Scholar
• Drapier D, Drapier S, Sauleau P et al. Pathological gambling secondary to dopaminergic therapy in Parkinson’s disease. J. Psychiatry Res.144(2–3), 241–244 (2006).
   Google Scholar
• Avanzi M, Baratti M, Cabrini S et al. Prevalence of pathological gambling in patients with Parkinson’s disease. Mov. Disord.21(12), 2068–2072 (2006).
   PubMed Web of Science ®Google Scholar
• Voon V, Hassan K, Zurowski M et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology66(11), 1750–1752 (2006).
   PubMed Web of Science ®Google Scholar
• Voon V, Thomsen T, Miyasaki JM et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch. Neurol.64(2), 212–216 (2007).
   PubMed Web of Science ®Google Scholar
• Foley P, Gerlach M, Double KL et al. Dopamine receptor agonists in the therapy of Parkinson’s disease. J. Neural Transm.111(10–11), 1375–1446 (2004).
   PubMed Web of Science ®Google Scholar